Latest News for: tslp

Edit

Windward Bio Expands Immunology Pipeline With WIN027, a Long-Acting, Clinical-Stage Bispecific Targeting TSLP and IL-13

Nasdaq Globe Newswire 22 Dec 2025
... QX027N), a potential best-in-disease, long-acting bispecific antibody targeting TSLP and IL-13.
Edit

Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe ...

Canada Newswire 01 Dec 2025
GB-0895 is an investigational, long-acting monoclonal antibody engineered with AI to target thymic stromal lymphopoietin (TSLP), a key driver of airway inflammation ... TSLP for at least six months.
Edit

Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI

PR Newswire 01 Dec 2025
These are the first global Phase 3 studies of a long-acting anti-TSLP antibody, marking a pivotal step as GB-0895 advances the promise of programmable biology ... TSLP for at least six months.
Edit

TSLP Inhibitors and TSLP Receptor Antagonists Competitor Analysis Report 2025: Early R&D in Tezspire Biosimilars ...

Nasdaq Globe Newswire 27 Nov 2025
Key market opportunities include expanding TSLP inhibitors and receptor antagonists beyond severe asthma ...
Edit

Belenos Pipeline Updates: First Clinical Data from Lead Asset BEL512, a Long-lasting Bispecific Targeting TSLP ...

Business Wire 11 Nov 2025
Key biomarkers of inflammation decreased, including TARC, IgE, IL-13, TSLP, and eotaxin-3 Favorable Safety.
Edit

Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody (Apogee Therapeutics Inc)

Public Technologies 10 Nov 2025
Key biomarkers of eosinophils and IL-5 showed depth of suppression in line with TSLP analogs and durability out to 6 months (limit of available follow up) ... In addition, a TSLP-targeting mAb may be used ...
Edit

ACAAI 2025 | CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Debut

Quad-City Times 07 Nov 2025
SUZHOU, China, Nov.
  • 1

Article Search

tools
×
×
×
×